cyrilzakka/clinical-trials huggingface dataset:
The Efficacy of LPPRP in the Treatment of Chondromalacia Patella

Chondromalacia patella(CP) is a common cause of anterior knee pain in the population under 50 years of age. CP is characterized by softening or varying degrees of damage to the patellar cartilage. The positive effects of leukocyte poor-platelet rich plasma (leukocyte poor-platelet rich plasma, LP-PRP) on cartilage repair and degenerative findings are known. However, there is no randomized controlled study on this subject in CP. The aim of this study is to investigate the effect of LP-PRP on pain, function, walking distance and magnetic resonance imaging (MRI) findings in CP patients.The study is the first to investigate the effect of LP-PRP on cartilage measurement with MRI in Chondromalasia Patella. Patients with anterior knee pain who applied to the physical therapy and rehabilitation outpatient clinic of Kayseri City Hospital, patients with Chondromalacia patella in MRI will be included in the study. A total of 40 patients will be randomized into 2 groups. The exercise program will be applied to both groups as a home program for 4 weeks.

A randomized, prospective, controlled study included 28 patients with MRI stage 2 and above Chondromalasia Patella findings. The patients were randomized into 2 groups, group 1 (the group in which 2 doses of suprapatellar bursa were injected with 2 doses of 3 cc LP-PRP at 1-week intervals and a 4-week home exercise program was given) and group 2 (the control group, the group given a 4-week home exercise program). Patients were tested on the Visual Analogue Scale (VAS) day, night and motion, Western Ontario McMaster Universities Osteoarthritis Index (WOMAC), 6-minute walk test (6MWT) at baseline,1st week, 4th week and 12th week and cartilage thickness, including defective cartilage thickness, and Chondromalasia Patella Outerbridge Staging were evaluated on MRI at baseline and 12th week. WOMAC value was taken as the primary outcome measure and MRI cartilage values were taken as the secondary outcome measure.

Clinic Responsible for Research: Physical Therapy and Rehabilitation Clinic of Kayseri City Hospital

Eligibility Criteria:
Inclusion Criteria:

* Chondromalasia Patella stage 2 and above in MRI requested from patients with chronic pain around the patella, who have increased pain in at least one of the activities that carry loads while the knee is flexed (squatting, stepping, running, jumping, jumping) after physical examination and clinical evaluation
* Patients with VAS 3 and above
* Patients over 18 years of age
* Patients without any deformity in the lower extremity

Exclusion Criteria:

* Coagulopathy and/or thrombocytopenia
* Cardiovascular instability or severe disease condition
* Presence of systemic infection or malignancy
* Pregnancy
* Intra-articular injection in the last 6 months
* Stage 3 and above meniscopathy in MRI
* Evidence or suspicion of rupture of the anterior cruciate ligament on MRI
Siderophore-profile in Allergic and Non-allergic Subjects

This study aims to profile the siderophore-content in the human gut from allergic and non-allergic subjects and to assess their contribution in iron homeostasis.

Iron is an essential nutrient for the majority of commensal bacteria, which commonly secrete siderophores to liberate iron from their surroundings. In several studies, a misbalanced microbiota has been demonstrated in allergics suggesting that also their siderophore profile is severely attenuated.

There are currently no data and very limited knowledge present on the composition of bacterial surviving factors in humans, or on their impact on the human immune system.

As such, 1) the iron status, 2) the microbial biota composition and the 3) siderophore-profile in allergics and non-allergics will be assessed.

Eligibility Criteria:
Inclusion Criteria:

* allergic and non-allergic volunteers

Exclusion Criteria:

* Patients will not be considered for the study if they have co-morbidities such as diabetes mellitus, disorders of the liver including hemochromatosis or kidney, autoimmune or metabolic diseases and malignancy or if they use of medications (e.g. antibiotics, PPIs) that influence the iron, inflammatory or microbial status. Further exclusion criteria are pregnancy, lactation; veganism, zinc, and iron supplementation and smoking. Volunteers will be asked to cease blood donation for at least three months' before recruitment and to cease other supplements for at least two weeks, e.g. vitamins, fish oil or minerals (other than zinc and iron).
ESSENTIAL-"The Studies of Oral Enoximone Therapy in Advanced Heart Failure"

To determine if low-dose enoximone therapy is an effective treatment for advanced chronic heart failure.

The study is a randomized, double-blind, multicenter, parallel group, placebo-controlled trial of oral enoximone in approximately 700 subjects with advanced chronic heart failure of either ischemic or nonischemic etiology receiving optimal conventional heart failure therapy.

Eligible subjects will be randomized in a 1:1 ratio to receive either enoximone or placebo at the Randomization Visit. The initial dose of study drug will be 25 mg t.i.d.(3xday) and will be administered immediately after randomization. Subjects who tolerate this initial dose will be continued on 25 mg t.i.d. for at least two weeks. After two weeks, eligible subjects will be titrated to 50 mg t.i.d. for the duration of the study.

Eligibility Criteria:
In order to be considered eligible subjects, the following entry criteria must be met:

* At least 18 years of age
* ischemic or nonischemic cardiomyopathy
* NYHA Class III or IV
* one hospitalization, or two outpatient visits, for the treatment of worsening heart failure within 12 months requiring the administration of I.V. heart failure therapy
* LVEDD \>3.2 cm/m2 or \>=6.0 cm
* LVEF of less than or equal to 30%
* concomitant treatment with optimal conventional heart failure therapy

Exclusion Criteria

Subjects who meet any one of the following criteria will be deemed ineligible for participation in the study:

Subjects on the following concomitant medications:

* Calcium antagonists other than amlodipine or felodipine
* Flecainide, encainide, propafenone, dofetilide or disopyramide
* Subjects receiving I.V. positive inotropic agents within seven days of the Screening Visit or Randomization Visit
* Subjects receiving a human B-type natriuretic peptide, including nesiritide, within seven days of the Screening Visit or Randomization Visit
* Subjects receiving oral or I.V. phosphodiesterase III inhibitors (PDEI III), including levosimendan and cilostazol, within seven days of the Screening Visit or Randomization Visit

  * Subjects with active hepatic (screening serum total bilirubin \>= 3.0 mg/dl (\>=51.3 umol/l), renal (screening serum creatinine \>= 2.0 mg/dl (=178.8 umol/l)), hematologic, gastrointestinal, immunologic, endocrine, metabolic, or central nervous system disease
  * Subjects with a serum potassium \<4.0 mEq/L or \>5.5 mEq/L (\<4.0 mmol/l or \>5.5 mmol/l) at Randomization Visit
  * Subjects with a magnesium level of \<1.0 mEq/L (\<0.5 mmol/l) at Randomization Visit (Visit 0)
  * Subjects with a serum digoxin of \>1.2 ng/ml (\>1.5 nmol/l) or a serum digitoxin of \>20 ng/ml (\>26.2 nmol/l) at the Randomization Visit are excluded. A target serum digoxin level of \<=1.0 ng/ml (\<=1.3 nmol/l) is recommended
Radial Shockwave for Spasticity in Children With CP or ABI

The goal of this clinical trial is to determine if radial Extracorporeal shockwave therapy (rESWT) reduces spasticity in children with Cerbral Palsy (CP) or traumatic brain injury (TBI). The main questions it aims to answer are:

* Is it feasible to implement radial shockwave therapy in conventional physiotherapy plan in children with CP or TBI?
* Is it safe and effective to use rESWT for reducing spasticity in children with CP or TBI? Participants will receive a 4 week therapy intervention, as add on to the conventional physio (usual care), including one rESWT session per week for a total of 4 sessions.


Eligibility Criteria:
Inclusion Criteria:

* cerebral palsy or acquired brain injury
* between 6-18 years old;
* gross motor function classification ≥2;
* experiencing spasticity in the lower limb (calf muscles, hip adductor muscles or hamstring muscles) and/or in the upper limb (biceps muscle, wrist flexor muscles, finger flexor muscles) with Modified Ashworth Scores (MAS) ≥1+.

Exclusion Criteria:

* recent (≤3 months) Botox injections or other recent (≤6 months) invasive intervention;
* local infections or wounds; neuropathy;
* severe organ dysfunction;
* severe psychosocial dysfunction that would not allow adhering to protocol;
* planned changes in medication dosage or medication scheme that might affect spasticity during a 4-month intervention and follow-up phase.
Short Term Outcomes After PRoton and PhotoN RadiOtherapy for IDH Mutated Grade 2 and 3 Gliomas

Rationale:

Proton beam therapy has recently become available for the treatment of patients with WHO grade 2 and 3 IDH mutated (IDHmt) glioma in the Netherlands. The dose distributions associated with proton therapy have substantially reduced the volume of the normal brain irradiated with low and intermediate radiotherapy doses. Whether this impacts rates of progressive disease or safety issues and how this compares with a similar population treated with photon therapy is currently unknown.

Objective:

To investigate short term outcomes after proton and photon radiotherapy for grade 2 and 3 IDHmt glioma.

Patients with grade 2 and 3 IDHmt glioma treated with proton therapy in Holland PTC, Maastro and UMC Groningen and referred Erasmus MC, Haaglanden MC, LUMC, Amsterdam UMC, Verbeeten Institute, Maastro, UMC Groningen, and Leuven University Hospital between 1st of January 2018 and the 30th of June 2022. The outcomes will be compared to those from patients with grade 2 and 3 IDHmt glioma treated with photon therapy in the same institutes and during the same period of time. The applied clinical target volume (CTV) margins and the chemotherapy are preferably similar for proton and photon therapy.

Retrospective data will be collected from the electronic records of each participating institute. For the primary outcome, data will be collected on interventions (radiotherapy, surgery, chemotherapy, medication) for either tumor progression or toxicity after radiotherapy. This will be used to calculate next intervention free survival as primary outcome.

For the secondary outcomes, data on survival, disease progression, pseudoprogression, and toxicity will be used to calculate overall survival, progression free survival, and pseudoprogression free survival, as well as toxicity incidence.

Eligibility Criteria:
Inclusion Criteria:

* Histopathologically confirmed WHO grade 2 or grade WHO 3 IDHmt glioma
* Treatment with radiotherapy delivered between 1 of January 2018 and completed before or on the 30th of June 2022
* Treatment with chemotherapy delivered after radiotherapy (PCV or Temozolomide)
* Age ≥ 18 years

Exclusion Criteria:

* Prior cranial radiotherapy
* Contra-indication for MRI imaging
* Chemotherapy delivered before radiotherapy
* Dose and fractionation other that standard dose (50.4 Gy in 28 fractions for Grade 2 and 59.5 Gy in 33 fractions for Grade 3)
* Combination photon and proton therapy
* Patient has previously opted-out of the use of their data for research
A Population-based Cohort of Osteoarthritis: the Xiangya Osteoarthritis Study

The purpose of this study is to examine the natural history, phenotypes and risk factors of osteoarthritis (OA) and pain at different joints, and to examine the association between OA structure changes, inflammation and pain for knee and hand OA.

Objectives:

1. To understand the natural history of osteoarthritis (OA) at different joints (knee, hip, hand, foot and lumbar).
2. To identify different phenotypes of OA (e.g., generalized OA, rapidly progressive knee and hand OA, tibiofemoral OA and patellofemoral OA), their association with pain (e.g., peripheral pain, central pain, nociceptive pain and neuropathic pain) and consequences.
3. To examine risk factors of OA (lifestyle habits, nutritional, metabolic, anatomical and genetic factors, etc.) at each joint as well as multiple joints.
4. To determine the association between x-ray structure change, ultrasound synovial changes and pain and other symptoms of OA at knee and hand joints within the large-sample community-based population.
5. To predict the progression of knee and hand OA within new-onset early-stage knee and hand OA patients, and to identify the rapidly progressive knee and hand OA phenotypes and their related risk factors.
6. To investigate the association between gut microbiota and OA.
7. To investigate the association between oral microbiota and OA.

Design: This is a prospective community-based cohort study.

Participants: Subjects included in this study were a randomly selected sample of residents, aged 50 years or older from rural mountainous communities of Longshan County, Hunan Province, China. 4000 people were planned to be recruited, divided into three sub-cohorts. 1,469 participants were enrolled in sub-cohort 1 in 2015, and two follow-ups have been completed in 2016 and 2017. 1,267 participants were enrolled in sub-cohort 2 in 2018. 1,340 participants were enrolled in sub-cohort 3 in 2019. Each sub-cohort will be followed every three years regularly.

Eligibility Criteria:
Inclusion Criteria:

1. 50 years old or above
2. Residents of the randomly selected communities

Exclusion Criteria:

1. Inability to give informed consent
2. Terminal or mental illness
3. Pregnant women
Edaravone Dexborneol Combining With Mechanical Thrombectomy in the Treatment of Acute Ischemic Stroke

Edaravone dexborneol, comprised of 2 active ingredients, edaravone and (+)-borneol, has been developed as a novel neuroprotective agent with synergistic effects of antioxidant and anti-inflammatory in animal models. The TASTE trial (Treatment of Acute Ischemic Stroke with Edaravone Dexborneol) administered edaravone dexborneol or edaravone alone to stroke patients within 48 hours after stroke onset, finding that 90-d functional outcome was better in edaravone dexborneol group. However, the TASTE trial excluded patients undergoing reperfusion therapy (i.e., intravenous thrombolysis and mechanical thrombectomy). Therefore, the investigators aim to evaluate the efficacy of edaravone dexborneol in addition to mechanical thrombectomy in the treatment of acute ischemic stoke.

This is a prospective, non-randomized clinical trial in multiple stroke centres of China. The total sample size will be 200. Patients with anterior-circulation large artery occlusion obtaining successful recanalization after mechanical thrombectomy (MT) will be assigned into edaravone dexborneol or standard medication treatment group based on whether or not receiving edaravone dexborneol. Only patients with edaravone dexborneol initiating within 48 hours of stoke onset at 37.5 mg/dose, once every 12 hours, and continuing for more than 7 days could be enrolled as edaravone dexborneol group. Patients in standard medication treatment group must not receive edaravone dexborneol. Other neuroprotective agents are not limited to use.

Eligibility Criteria:
Inclusion Criteria:

* Patients presenting with anterior circulation acute ischemic stroke
* Patients aged between 18-80 years.
* CTA or DSA verified arterial occlusion of ICA, M1 or M2.
* NIHSS on admission 4 - 26
* Baseline CTP verified infarct core \< 70 ml, penumbra \> 10 ml, hypoperfusion/core \> 1.8
* Undergoing mechanical thrombectomy within 24 hours of stroke onset. For wake-up stroke, the onset time is determined as the midpoint of last-seen-well and discovered time

Exclusion Criteria:

* Patients without recanalization (TICI 0,1, 2a)
* Pre-existing neurological disability (a score greater than 2 on the mRS)
* Contraindication of edaravone dexborneol
Application of Auricular Point Sticking in Patients With Taste Alteration

To explore the intervention effect of auricular point sticking on chemotherapy-induced taste alterations in cancer patients, and analyze its relationship with quality of life, nutritional status and psychology of patients.

Taste alteration is a common adverse reaction in patients with chemotherapy. The incidence of taste alteration varies with chemotherapy drugs, ranging from 36% to 84%, among which platinum chemotherapeutic drugs are most likely to cause severe taste alteration. The taste alteration does not pose a serious threat to the life of patients, so it is often ignored by patients and medical staff. Dysgeusia is positively correlated with the loss of appetite, which can directly lead to the loss of appetite and insufficient intake of nutrients in patients, and even stimulate patients' anxiety, psychological pain and other negative emotions. In severe cases, it can cause malnutrition, reduce the chemotherapy compliance of cancer patients, and ultimately reduce the quality of life of patients. Therefore, for patients with platinum chemotherapy, it is necessary to pay close attention to the change of taste during chemotherapy, and apply effective nursing interventions to pay attention as soon as possible, so as to improve the quality of life of patients.

Eligibility Criteria:
Inclusion Criteria:

1. Patients with malignant tumors diagnosed by histopathology or pathology;
2. Age ≥18 years old;
3. Patients who received platinum-based chemotherapy and completed at least one cycle of chemotherapy;
4. According to the chemotherapy-induced taste Changes Scale (CiTAS), the score of patients was ≥6;
5. Patients voluntarily participated in the treatment with good compliance and adherence.

Exclusion Criteria:

1. Patients with treatment plan adjustment or concurrent radiotherapy;
2. Patients with abnormal taste and malnutrition caused by various reasons before chemotherapy;
3. Patients with inflammation of the external ear or eczema, ulcers, chilblain in the pressing area;
4. Allergic or intolerant to adhesive stickers;
5. Those who were lost to follow-up or withdrew voluntarily;
6. Patients enrolled in other studies at the same time.
More Added Value of Therapeutic Education in the Management of Patients With Rheumatoid Arthritis (ETP-PR)

Taking into account the recommendations of the Health Authority \[1\] and the application of patients' associations, we have structured a course of therapeutic education includes three stages for patients with rheumatoid arthritis and followed at Nantes University Hospital. Step 1: initial interview with a nurse patient education for diagnosis and education with the patient to choose three subjects from among 10 offered him problematic; Step 2: Orientation in an educational path that provides access to 6 months group workshops (3 maximum) and / or interviews tailored to the three selected topics; Step 3: final interview with a nurse said therapeutic education formative assessment to take stock. The main objective of our work is to ensure that the patient finds it easier solutions to the three problematic topics him after 6 months of education after six months without treatment.


Eligibility Criteria:
Inclusion Criteria:

* Patient presenting at clinics for Rheumatology or the Rheumatology Day Hospital at the University Hospital or hospitalized in the department of Rheumatology
* Men or women
* Having signed the consent
* major
* Affiliated to social security or covered by the CMU
* Patient with rheumatoid arthritis meeting the ACR criteria
* Patient with rheumatoid arthritis stable for at least 6 months (change in DAS 28 \<1.2)

Exclusion Criteria:

* Patient can not understand the information
* Patient confined to bed or chair, unable to care for himself or not doing with difficulty
* pregnant patient
* minors
* Adults under guardianship
Circadian Rhythm of Erythropoietin And Melatonin in Renal Disease

Rationale: Investigation of the circadian rhythm of erythropoietin and melatonin in patients with various degrees of renal insufficiency

Objectives:

Primary objective: Is there a circadian rhythm of epo and melatonin in patients with various degrees of renal insufficiency?

Primary Objective: Is there a circadian rhythm of epo and melatonin in patients with various degrees of renal insufficiency compared to patients with a normal renal function?

Secondary Objective: Is there a circadian rhythm of cortisol and IGF in patients with various degrees of renal insufficiency?

Secondary Objective: Is there a circadian rhythm of cortisol and IGF in patients with various degrees of renal insufficiency compared to patients with a normal renal function?

Study design: Comparative study in 4 groups with various degrees of renal insufficiency, duration for each patient 24 hrs. Total duration of study 12 months, patients admitted to the hospital (on nursing ward)

Study population: Patients with various degrees of renal insufficiency

Main study parameters/endpoints: Analysis of the existence of a circadian rhythm in patients with a normal renal function and in patients with variable degrees of renal insufficiency

Nature and extent of the burden and risks associated with participation, benefit and group relatedness: Better knowledge of the circadian rhythm in renal insufficiency. This could lead to a more efficient administration of erythropoietin and melatonin in the future.

Extent of burden is 1 venapunction for placement of infusion needle, the withdrawal of 11 times 5 ml blood in 24 hrs, continuous measurement of body temperature via capsule, 24-hour continuous ambulant blood pressure monitoring.


Eligibility Criteria:
Inclusion criteria:

* Patient with various degrees of renal insufficiency, stable creatinin clearance: minimum 10 ml/min (measured with MDRD), admitted to our hospital
* Informed Consent
* Man/Women between 18 and 85 years
* Understanding and knowledge of the dutch language

Exclusion criteria:

* Instable angina pectoris, heart failure NYHA class IV
* Therapy with erythropoetin, melatonin and hypnotics
* Acute renal failure or rapidly progressive glomerulonephritis
* Bleeding or hemolysis as a cause of anemia
* Deficiency of iron, folate and/or vitamin B12
* Presence of chronic inflammatory disease or clinically significant infection
* Hemoglobinopathies
* Alcohol and/or drug abuse
* Enrolment in another study
* Any kind of disorder that compromises the ability of the subject to give written informed consent and/or to comply with study procedures